Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

(Reuters) - The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price ...

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker ...

Insanely beautiful and glossy people are telling me why I should or shouldn't take weight loss drugs. Warning: This article contains details of body image and ... as Ozempic, Wegovy or Saxenda ...

To help them cope with the side effects, patients are started on a low dose of the weight-loss jabs, and it is gradually increased, month by month. Image caption, Wegovy is injected using a pen ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock ... Novo Nordisk’s Wegovy are both ...